

PRESIDENT

Tomris OZBEN
Akdeniz University - Medical Faculty
Department of Clinical Biochemistry
07070 Antalya - Türkiye

PRESIDENT-ELECT

Nader RIFAI
Department of Laboratory Medicine
Boston Children's Hospital
Harvard Medical School
MA 02115 - USA

SECRETARY

Sergio BERNARDINI
University Tor Vergata
00174 Rome - Italy

TREASURER

Alexander HALIASSOS
ESEAP - Greek Proficiency Testing Scheme
for Clinical Laboratories
GSCC-CB
GR-106 76 Athens - Greece

CORPORATE REPRESENTATIVE

Tricia RAVALICO
Director, Scientific Leadership and Education
Medical and Scientific Affairs
Core Diagnostics Abbott
IL 60064 - USA

**IFCC REGIONAL FEDERATION
REPRESENTATIVES**

African Federation of Clinical Chemistry (AFCC)

Rajiv ERASMUS
Dept of Chemical Pathology
Tygerberg, 7505 - South Africa

Arab Federation of Clinical Biology (AFCB)

Myrna GERMANOS HADDAD
Syndicate of Clinical Biologists in Lebanon
Lebanese Order of Physicians Bldg
Beirut - Lebanon

**Asia-Pacific Federation for Clinical Biochemistry and
Laboratory Medicine (APFCB)**

Tony BADRICK
Chief Executive
The Royal College of Pathologists of Australia
St Leonards NSW - Australia

**European Federation of Clinical Chemistry and
Laboratory Medicine (EFLM)**

Tomas ZIMA
Head of Institute of Medical Biochemistry and
Laboratory Diagnostics of the First Faculty of Medicine
Charles University and General University Hospital
CZ-121 08 Prague 2 - Czech Republic

**Latin-American Confederation of Clinical
Biochemistry (COLABIOCLI)**

Eduardo FREGGIARO
Fundación Bioquímica Argentina - President
Ciudad Autónoma de Buenos Aires
C1053ABW - Argentina

**North American Federation of Clinical Chemistry and
Laboratory Medicine (NAFCC)**

Shannon HAYMOND
Ann & Robert H. Lurie Children's Hospital of Chicago
SVP and Chief Department of Pathology
and Laboratory Medicine
Chicago, IL 60611-2605 - USA

IFCC Office

Via Carlo Farini, 81
20159 Milano – Italy
Tel: +39 02 66809912
Email: ifcc@ifcc.org
website: <http://www.ifcc.org/>

To: IFCC Corporate Members

Dear IFCC Corporate Representative,

The **IFCC Task Force of Corporate Members (TF-CM)** was established to strengthen collaboration between IFCC and its Corporate Members, and to better address industry-specific needs and challenges. The **IFCC TF-CM** reports directly to the IFCC Executive Board. Its objectives are to:

- Enhance the engagement of Corporate Members within IFCC;
- Facilitate discussion among Corporate Members and identify areas of common interest, including opportunities to advance the practice of laboratory medicine;
- Ensure active and ongoing dialogue between Corporate Members and the IFCC Executive Board.

As a result of term completions, **the Chair and one Member** of the TF-CM will conclude their service at the end of December 2026. The current Chair is keeping exceptionally both the Chair and Member positions at the TF-CM. Although her term as Chair will end, she will continue to serve on the TF-CM in her capacity as the Corporate Members' Representative on the IFCC Executive Board. In this role, she will facilitate communication between the TF-CM, the Executive Board, and the entire Corporate Members as their elected representative.

We are therefore inviting nominations for the Chair and Member positions of TF-CM from committed, enthusiastic and actively contributing individuals with experience in the in vitro diagnostic (IVD) industry. Successful candidates will commence their three-year term in January 2027.

The new Chair and member of the Task Force-Corporate Members will be selected by the IFCC Executive Board from among the nominations received. As IFCC currently has 61 Corporate Members, and to encourage broader participation, only one representative from any company may serve on the TF-CM at any given time.

<https://ifcc.org/executive-board-and-council/eb-task-forces/task-force-corporate-members/>

If you, as the Corporate Representative are interested in either position (Chair or Member) or if you wish to nominate a colleague from your company to the TF-CM, please submit the following documentation to the IFCC President (president@ifcc.org) and Ms. Paola Bramati at the IFCC Office (paola.bramati@ifcc.org) by June 30, 2026:

- A formal nomination letter for the candidate;
- A letter outlining the candidate's interest in the position, the contributions they would be expected to make, any suggestions for topics the Task Force to address, and a short curriculum vitae;
- A confirmation document that your company supports the nomination.

We look forward to receiving nomination of your company and to further strengthening the collaboration between IFCC and its Corporate Members through the work of the TF-CM.

Yours sincerely



Prof. Tomris Ozben
IFCC President